Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C65530
http://purl.obolibrary.org/obo/NCIT_C65530
|
|---|---|
| Preferred Name | Erlotinib |
| Definitions |
A quinazoline derivative with antineoplastic properties. Competing with adenosine triphosphate, erlotinib reversibly binds to the intracellular catalytic domain of epidermal growth factor receptor (EGFR) tyrosine kinase, thereby reversibly inhibiting EGFR phosphorylation and blocking the signal transduction events and tumorigenic effects associated with EGFR activation.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | A quinazoline derivative with antineoplastic properties. Competing with adenosine triphosphate, erlotinib reversibly binds to the intracellular catalytic domain of epidermal growth factor receptor (EGFR) tyrosine kinase, thereby reversibly inhibiting EGFR phosphorylation and blocking the signal transduction events and tumorigenic effects associated with EGFR activation. |
|---|---|
| prefLabel | Erlotinib
|
| label | Erlotinib
|
| Has_Salt_Form | |
| CHEBI_ID | CHEBI:114785
|
| code | C65530
|
| Has_Target | |
| prefixIRI | NCIT:C65530
|
| in_subset |
See more
See less
|
| Display_Name | Erlotinib
|
| Preferred_Name | Erlotinib
|
| FDA_UNII_Code | J4T82NDH7E
|
| Contributing_Source |
CTRP
FDA
|
| Chemical_Formula | C22H23N3O4
|
| Maps_To | Erlotinib
|
| CAS_Registry | 183321-74-6
|
| Legacy Concept Name | Erlotinib_Base
|
| type | |
| Is_Value_For_GDC_Property | |
| subClassOf | |
| Semantic_Type | Pharmacologic Substance
|
| UMLS_CUI | C1135135
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |